Compare Amgen, Inc. (AMGN) vs Invesco DB Agriculture Fund (DBA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Invesco DB Agriculture Fund — how do they compare? Amgen, Inc. trades at $362.12 (market cap $196.12B), while Invesco DB Agriculture Fund trades at $27.66. The key difference: Amgen, Inc. pays a 2.77% dividend while Invesco DB Agriculture Fund pays none, and Amgen, Inc. is trading nearer its 52-week high, Invesco DB Agriculture Fund nearer its low. Which is the better fit depends on your goals.
| AMGN | DBA | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | — |
52-Week High | $388.16 | $28.73 |
52-Week Low | $271.18 | $25.44 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
DBA (Invesco DB Agriculture Fund) trades at $27.77, up 0.22% today, with a bullish technical signal supported by moving averages but tempered by overbought oscillators. The ETF tracks agricultural commodities including corn, soybeans, wheat, and livestock, benefiting from recent supply disruptions and strong commodity price trends. Recent news highlights weather impacts on Brazilian coffee harvests and China's $17 billion U.S. crop purchase commitment through 2028.
The agricultural commodity exposure positions DBA for potential gains amid global supply constraints, though high RSI levels suggest near-term consolidation risk. Key support sits at $27 with resistance at $28-29. Investors should monitor crop reports and geopolitical developments affecting commodity markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Invesco DB Agriculture Fund
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →
